The Respimat® success story: Boehringer Ingelheim doubles its production capacity

Boehringer IngelheimSuccessful treatment of respiratory diseases also depends on how much of the active substance enters the patient's lung. Boehringer Ingelheim's Respimat® Soft Inhaler and its long-lasting aerosol cloud effectively transport the active substance into the lung. As a result of increasing demand for this innovative inhalation system, the research-driven pharmaceutical company Boehringer Ingelheim is investing approximately EUR 85 million in its Dortmund facility to double the Respimat® production to 44 million inhalers annually by 2015. This expansion will also create more than 100 new jobs in Dortmund at full capacity utilisation.

"We expect that the Respimat® business will continue its strong growth. For this reason, Boehringer Ingelheim is now laying the symbolic foundation stone to expand production capacity for the Respimat® Soft Inhaler at the Dortmund facility. In future, we will continue to meet the increasing demand, while at the same time fulfilling our claim to provide patients with innovative medications," stated Professor Wolfram Carius, member of Boehringer Ingelheim's Board of Managing Directors in charge of Biopharmaceuticals and Operations.

"Doubling our Respimat® production capacity will allow us to produce up to 44 million inhalers annually in the future. The success story of Respimat® continues." The Respimat® Soft Inhaler is produced in Dortmund by subsidiary Boehringer Ingelheim microParts GmbH. Part of the Boehringer Ingelheim group since 2004, it manufactures products for global distribution of the pharmaceutical company.

"North Rhine-Westphalia is Germany's industrial hub - and by investing millions here in Dortmund, Boehringer Ingelheim is underscoring the importance of our state to industry," emphasised Garrelt Duin, Minister of Economic Affairs, Energy, Industry, SMEs and Trade for the State of North Rhine-Westphalia at the start of production capacity expansion in Dortmund. "To develop such high technology, a long-term effort is required before the whole thing really pays off," said Duin. "North Rhine-Westphalia and the City of Dortmund are very fortunate that as a family-owned company, Boehringer Ingelheim has the necessary stamina."

More than 450 employees are currently employed for the manufacture of Respimat® Soft Inhalers in Dortmund at Boehringer Ingelheim microParts GmbH. Respimat® is filled with its active pharmaceutical substances at the company's headquarters in Ingelheim, from where it is distributed around the world.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...